Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

81. Contribution of oxytocin receptor polymorphisms to amygdala activation in schizophrenia spectrum disorders Full Text available with Trip Pro

Contribution of oxytocin receptor polymorphisms to amygdala activation in schizophrenia spectrum disorders Oxytocin has been proposed to mediate amygdala dysfunction associated with altered emotion processing in schizophrenia, but the contribution of oxytocin pathway genes is yet to be investigated.To identify potential different contributions of three oxytocin receptor polymorphisms (rs53576, rs237902 and rs2254298) between patients with schizophrenia spectrum disorders (SCZ), affective

2016 BJPsych open

82. Effect of transcranial direct current stimulation (tDCS) over the prefrontal cortex combined with cognitive training for treating schizophrenia: a sham-controlled randomized clinical trial. Full Text available with Trip Pro

Effect of transcranial direct current stimulation (tDCS) over the prefrontal cortex combined with cognitive training for treating schizophrenia: a sham-controlled randomized clinical trial. We report a transcranial direct current stimulation (tDCS) protocol over the dorsolateral prefrontal cortex (DLPFC) combined with cognitive training in schizophrenia.We assessed psychotic symptoms in nine patients using the Positive and Negative Syndrome Scale (PANSS). All evaluations were scored at baseline (...) severity scores (p = 0.619). Mixed analysis of variance (ANOVA) showed no statistical significance between the groups regarding final PANSS scores.The results failed to demonstrate that the concomitant use of tDCS and cognitive training is effective to improve clinical outcomes in patients with schizophrenia. The present findings should be analyzed with care, considering the small sample size. Larger controlled trials on electric/cognitive stimulation should be produced in order to enhance therapeutic

2016 Trends in psychiatry and psychotherapy Controlled trial quality: uncertain

83. Loss of relational continuity of care in schizophrenia: associations with patient satisfaction and quality of care Full Text available with Trip Pro

Loss of relational continuity of care in schizophrenia: associations with patient satisfaction and quality of care Users of mental health service are concerned about changes in clinicians providing their care, but little is known about their impact.To examine associations between changes in staff, and patient satisfaction and quality of care.A national cross-sectional survey of 3379 people aged 18 or over treated in secondary care for schizophrenia or schizoaffective disorder.Nearly 41.9 (...) continuity of care for such patients.M.J.C. was co-chair of the expert advisory group on the NICE quality standard on Service User Experience in Adult Mental Health. S.J.C. has previously been a member of the Health and Social Care Board Northern Ireland Formulary Committee. D.S. received a speaker's fee from Janssen Cilag in 2011. He is a topic expert on NICE guideline for psychosis and schizophrenia in children and young people and a board member of National Collaborating Centre for Mental Health.©

2016 BJPsych open

84. Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial. Full Text available with Trip Pro

Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial. Clozapine causes significant metabolic disturbances including obesity and type 2 diabetes. Recent evidence that reduced glucagon-like-peptide-1 (GLP-1) may contribute to aetiology of clozapine-associated metabolic dysregulation suggests a potential therapeutic role for GLP-1 agonists.This open-label, pilot randomised controlled trial (...) evaluates the effect of exenatide in clozapine-treated obese adults who have schizophrenia, with or without poorly controlled diabetes. Sixty out-patients will be randomised to once weekly extended release exenatide or treatment as usual for 24 weeks.To evaluate the feasibility of larger studies regarding methodology, acceptability, tolerability and estimate efficacy for glycaemic control or weight loss. Secondary outcomes are psychosis severity and metabolic parameters.This is the first trial

2016 BJPsych open Controlled trial quality: uncertain

85. Psychiatric symptoms in individuals who use ketamine versus methamphetamine-implications for glutamatergic and dopaminergic model for schizophrenia: a cohort study. Full Text available with Trip Pro

Psychiatric symptoms in individuals who use ketamine versus methamphetamine-implications for glutamatergic and dopaminergic model for schizophrenia: a cohort study. Psychiatric symptoms in individuals who use ketamine versus methamphetamine—implications for glutamatergic and dopaminergic model for schizophrenia: a cohort study - The Lancet Go search This Journal Full Site Access provided by , S67, October 01, 2016 Powered By Mendeley Psychiatric symptoms in individuals who use ketamine versus (...) methamphetamine—implications for glutamatergic and dopaminergic model for schizophrenia: a cohort study Yanhui Liao Affiliations Mental Health Institute of the Second Xiangya Hospital, Central South University, Hunan 410011, China National Clinical Research Center on Mental Disorders & National Technology Institute on Mental Disorders, Hunan 410011, China Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, Hunan 410011, China Chang Qi Affiliations Mental Health Institute of the Second Xiangya

2016 Lancet

87. WITHDRAWN: Risperidone versus other atypical antipsychotic medication for schizophrenia. Full Text available with Trip Pro

WITHDRAWN: Risperidone versus other atypical antipsychotic medication for schizophrenia. Risperidone is one of a number of 'atypical antipsychotics' which are currently being marketed for the treatment of those with schizophrenia, largely on the basis of claims of improved tolerability and effectiveness compared to much cheaper conventional antipsychotics. The efficacy of risperidone has already been compared to conventional drugs, but it remains unclear how risperidone compares with other (...) atypical antipsychotic drugs such as clozapine.To determine the effects of risperidone compared with other atypical antipsychotic drugs for schizophrenia.Electronic searches of Biological Abstracts (1980-1999), The Cochrane Library (Issue 1, 2000), The Cochrane Schizophrenia Group's Register (January 1999), EMBASE (1980-1999), MEDLINE (1966-1999), LILACS (1982-1999), PSYNDEX (1977-1999) and PsycLIT (1974-1999) were undertaken. In addition, pharmaceutical databases on the Dialog Corporation Datastar

2016 Cochrane

88. Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial (Abstract)

Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial A substantial proportion of women with schizophrenia experience debilitating treatment-refractory symptoms. The efficacy of estrogen in modulating brain function in schizophrenia has to be balanced against excess exposure of peripheral tissue. Raloxifene hydrochloride is a selective estrogen receptor modulator (mixed estrogen agonist/antagonist) with potential psychoprotective (...) effects and fewer estrogenic adverse effects.To determine whether adjunctive raloxifene therapy reduces illness severity in women with refractory schizophrenia.This 12-week, double-blind, placebo-controlled, randomized clinical trial with fortnightly assessments was performed at an urban tertiary referral center and a regional center from January 1, 2006, to December 31, 2014. Participants included 56 women with schizophrenia or schizoaffective disorder and marked symptom severity despite substantial

2016 EvidenceUpdates Controlled trial quality: predicted high

89. Olanzapine (ZypAdhera) - maintenance treatment of adult patients with schizophrenia

Olanzapine (ZypAdhera) - maintenance treatment of adult patients with schizophrenia Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: All Wales Medicines Strategy Group. Final Appraisal Recommendation – 1516: Olanzapine (ZypAdhera ® ) 210 mg, 300 mg, and 405 mg, powder and solvent for prolonged release suspension for injection. June 2016. Final Appraisal Recommendation Advice No: 1516 – June 2016 Olanzapine (...) of patients/patient carers (where available) and the lay member perspective. This recommendation has been ratified by the Minister for Health and Social Services and will be considered for review every three years. Recommendation of AWMSG Olanzapine (ZypAdhera ® ) is recommended as an option for restricted use within NHS Wales. Olanzapine (ZypAdhera ® ) is licensed for the maintenance treatment of adult patients with schizophrenia sufficiently stabilised during acute treatment with oral olanzapine

2016 All Wales Medicines Strategy Group

90. Bulking up the hippocampus in schizophrenia: a role for 5-HT1A agonists? Full Text available with Trip Pro

Bulking up the hippocampus in schizophrenia: a role for 5-HT1A agonists? The volume of the hippocampus is reduced in patients with schizophrenia, and this deficit tends to become more pronounced with chronicity. Newer antipsychotics may protect against the progressive reductions in hippocampal volume while preliminary data offer hope that specific antipsychotics may act to reverse it.None.© The Royal College of Psychiatrists 2016. This is an open access article distributed under the terms

2016 BJPsych open

91. Cariprazine (Vraylar) for schizophrenia and acute manic or mixed episodes in bipolar I disorder

Cariprazine (Vraylar) for schizophrenia and acute manic or mixed episodes in bipolar I disorder Cariprazine (Vraylar) for schizophrenia and acute manic or mixed episodes in bipolar I disorder Cariprazine (Vraylar) for schizophrenia and acute manic or mixed episodes in bipolar I disorder HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc (...) .. Cariprazine (Vraylar) for schizophrenia and acute manic or mixed episodes in bipolar I disorder. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2016 Authors' conclusions Description of Technology: Cariprazine (Vraylar) is an orally administered atypical antipsychotic agent used to treat patients with acute exacerbation of schizophrenia or acute manic or mixed episodes associated with bipolar I disorder. Among antipsychotic drugs, the binding affinity profile of cariprazine is most similar

2016 Health Technology Assessment (HTA) Database.

92. Dietary advice for people with schizophrenia. (Abstract)

Dietary advice for people with schizophrenia. People with serious mental illness have consistently higher levels of mortality and morbidity than the general population. They have greater levels of cardiovascular disease, metabolic disease, diabetes, and respiratory illness. Although genetics may have a role in the physical health problems of these people, lifestyle and environmental factors such as smoking, obesity, poor diet, and low levels of physical activity play a prominent part.To review (...) the effects of dietary advice for schizophrenia and schizophrenia-like psychosis.We searched the Cochrane Schizophrenia Group's Trials Register (September 09, 2013 and February 24, 2016).We planned to include all randomised clinical trials focusing on dietary advice versus standard care.The review authors (RP, KTP) independently screened search results but did not identify any studies that fulfilled the review's criteria.We did not identify any studies that met our inclusion criteria.Dietary advice has

2016 Cochrane

93. Refugee migration and risk of schizophrenia and other non-affective psychoses: cohort study of 1.3 million people in Sweden. Full Text available with Trip Pro

Refugee migration and risk of schizophrenia and other non-affective psychoses: cohort study of 1.3 million people in Sweden. To determine whether refugees are at elevated risk of schizophrenia and other non-affective psychotic disorders, relative to non-refugee migrants from similar regions of origin and the Swedish-born population.Cohort study of people living in Sweden, born after 1 January 1984 and followed from their 14th birthday or arrival in Sweden, if later, until diagnosis of a non (...) sub-Saharan Africa had similarly high rates relative to the Swedish-born population.Refugees face an increased risk of schizophrenia and other non-affective psychotic disorders compared with non-refugee migrants from similar regions of origin and the native-born Swedish population. Clinicians and health service planners in refugee receiving countries should be aware of a raised risk of psychosis in addition to other mental and physical health inequalities experienced by refugees.Published

2016 BMJ

94. Understanding causes of and developing effective interventions for schizophrenia and other psychoses Full Text available with Trip Pro

Understanding causes of and developing effective interventions for schizophrenia and other psychoses Understanding causes of and developing effective interventions for schizophrenia and other psychoses Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need

2016 NIHR HTA programme

95. Mortality and Cumulative Exposure to Antipsychotics, Antidepressants, and Benzodiazepines in Patients With Schizophrenia: An Observational Follow-Up Study Full Text available with Trip Pro

Mortality and Cumulative Exposure to Antipsychotics, Antidepressants, and Benzodiazepines in Patients With Schizophrenia: An Observational Follow-Up Study Although mortality related to psychotropic medications has received much attention in recent years, little is known about the relationship between risk of death and cumulative antipsychotic load, and even less about the relationship between mortality and cumulative exposure to antidepressants or benzodiazepines. The authors examined (...) these relationships using nationwide databases.The authors used prospectively collected nationwide databases to identify all individuals 16-65 years of age with a schizophrenia diagnosis (N=21,492) in Sweden. All-cause and cause-specific mortality rates were calculated as a function of cumulative low, moderate, and high exposure to antipsychotics, antidepressants, and benzodiazepines from 2006 through 2010.Compared with no exposure, both moderate (adjusted hazard ratio=0.59, 95% CI=0.49-0.70) and high (adjusted

2016 EvidenceUpdates

96. Schizophrenia. Full Text available with Trip Pro

Schizophrenia. Schizophrenia is a complex, heterogeneous behavioural and cognitive syndrome that seems to originate from disruption of brain development caused by genetic or environmental factors, or both. Dysfunction of dopaminergic neurotransmission contributes to the genesis of psychotic symptoms, but evidence also points to a widespread and variable involvement of other brain areas and circuits. Disturbances of synaptic function might underlie abnormalities of neuronal connectivity

2016 Lancet

97. Origin and schizophrenia in young refugees and inter-country adoptees from Latin America and East Africa in Sweden: a comparative study Full Text available with Trip Pro

Origin and schizophrenia in young refugees and inter-country adoptees from Latin America and East Africa in Sweden: a comparative study Migrants' socioeconomic adversity has been linked to schizophrenia.To investigate whether the more favourable socioeconomic situation of adoptees prevents them from the high risk of schizophrenia found in other migrants.Register study in a cohort of refugees and inter-country adoptees aged 16-40 years, born in East Africa (n=8389), Latin America (n=11 572 (...) ) and 1.2 million native Swedes. Cox-regression models estimated hazard ratios (HRs) of schizophrenia in data from psychiatric care.Despite diverse income levels, HRs for schizophrenia were similar for refugees and adoptees, with East Africans having the highest HRs: 5.83 (3.30-10.27) and 5.80 (5.03-6.70), followed by Latin Americans: HRs 3.09 (2.49-3.83) and 2.31 (1.79-2.97), compared with native Swedes. Adjustment for income decreased these risks slightly for refugees, but not for adoptees.This study

2016 BJPsych open

98. Guidance addressing all aspects of the care of people with schizophrenia and related disorders. Includes correct diagnosis, symptom relief and recovery of social function

Guidance addressing all aspects of the care of people with schizophrenia and related disorders. Includes correct diagnosis, symptom relief and recovery of social function First published in Australian and New Zealand Journal of Psychiatry 2016, Vol. 50(5) 1-117. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders Cherrie Galletly 1,2,3 , David Castle 4 , Frances Dark 5 , Verity Humberstone 6 , Assen (...) Jablensky 7 , Eóin Killackey 8,9 , Jayashri Kulkarni 10,11 , Patrick McGorry 8,9,12 , Olav Nielssen 13 and Nga Tran 14,15 Abstract Objectives: This guideline provides recommendations for the clinical management of schizophrenia and related disorders for health professionals working in Australia and New Zealand. It aims to encourage all clinicians to adopt best practice principles. The recommendations represent the consensus of a group of Australian and New Zealand experts in the management

2016 Royal Australian and New Zealand College of Psychiatrists

99. Measures to support positive lifestyle changes in people with schizophrenia

alcohol, there are too few studies on patients with schizophrenia to be able to draw any conclusions. • There are no published studies of the cost effective - ness of behavioural measures to promote physical activity and a healthy diet, nor of drug treatment to promote abstinence and limit alcohol depen- dence and abuse. • SBU’s report from 2012 showed that the care of people with schizophrenia and schizophrenic conditions was in many ways inferior to that re- ceived by others, even though their need (...) Measures to support positive lifestyle changes in people with schizophrenia 1 Measures to support positive lifestyle changes in people with schizophrenia sbu report | a systematic review of the scientific evidence 2014 | www.sbu.se/232 Summary Schizophrenia is a chronic, debilitating mental dis- order. On average, life expectancy is 15 years shorter for men and 12 years shorter for women than for the rest of the population. Factors such as smoking, alco- hol/drug abuse, inadequate diet and lack

2016 Swedish Council on Technology Assessement

100. Pharmacological interventions: Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia?

Pharmacological interventions: Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia? Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia? | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia? Article Text Further commentaries Electronic pages

2016 Evidence-Based Mental Health